237690

ST PHARM is a contract development and manufacturing organization (CDMO) specializing in gene therapy and nucleic acid-based therapeutics. The company provides CDMO services for oligonucleotides, small-molecule APIs, and mRNA therapeutics, including the development of 5' capping technologies and lipid nanoparticle (LNP) delivery systems. ST PHARM also engages in proprietary drug discovery through a virtual R&D model, with pipeline candidates including the HIV treatment STP0404 (Pirmitegravir) and the oncology agent STP1002 (Basroparib). The company operates subsidiaries and partners such as VERNAGEN, Levatio Therapeutics, and AnaPath Services to support its integrated value chain from research to commercial manufacturing. Founded in 1983 as Samchully Pharm and joined the Dong-A Solbio Group in 2010, ST PHARM serves global pharmaceutical and biotechnology clients with cGMP-certified facilities in Korea.

Summarised from the company's own disclosures, fiscal year ended Jun 2026

Industry Drug Manufacturers - Specialty & Generic Homepage stpharm.co.kr
Sector Healthcare IR page —
Tags
oligonucleotide cdmo, mrna therapeutics, small-molecule api, gene therapy, lnp technology, 5' capping, sgrna, hiv treatment, oncology, vaccine development, virtual r&d, STP0404, Pirmitegravir, STP1002, Basroparib, STP2104, SmartCap, STLNP, VERNAGEN, Levatio Therapeutics, AnaPath Services, AnaPath Research, Quantoom Bioscience, Evonik Industries, CEPI, Multiverse Pharma, Genevant
Press page —

Metrics

Valuation  
Market cap —
Market cap (USD) —
P/E —
PEG —
P/BV —
P/S —
P/OCF —
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE 10.0%
ROI 9.3%
ROIC 8.6%
Profit margin 16.6%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) 45.1%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock —
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) —
Quality score 54.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014
Revenue 331.681B 273.751B 284.992B 249.322B 165.642B 124.109B 93.257B 97.738B 202.8B 200.362B 138.052B 96.54B
Net profit 54.992B 34.712B 19.581B 18B 3.312B -12.147B -18.529B -9.268B 44.997B 61.426B 25.189B 5.466B
Free cash flow -33.082B 26.646B -41.946B -53.448B -44.522B -37.924B -36.737B -16.399B 26.742B 34.75B 13.719B -16.602B

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (KRW) 18B 29.9B 15.9B 35.7B 45.4B 62.9B 94.2B 121B 67.8B 96.7B
↳ YoY growth +35.8% +66.4% -47.0% +125.2% +27.3% +38.5% +49.7% +28.0% -43.7% +42.5%
↳ 5y CAGR +28.0% +28.5% +25.8% +50.0% +13.7% +16.3%
Other receivables (KRW) — 115M — — — — — — — —
Borrowings, current (KRW) 19.5M 19.5M 3.4B 19.5M 4.78B 15B 114B 29.2B 72.2B 76.5B
Borrowings, non-current (KRW) 137M 117M 97.5M 15.1B 126B — 16.7B 160B 43.3B 0.00
Bonds payable (KRW) — — — — — — 85.9B 151B — —
Lease liabilities (KRW) — — 1.91B 896M 6.81B 1.07B 3.67B 3.18B 2.67B 2.18B
Cash and deposits (KRW) 55.2B 72.3B 47.7B 12.8B 38.6B 39.2B 50.2B 50.1B 63.4B 30.5B
Intangible assets (KRW) 1.08B 1.21B 1.41B 8B 10B 12.6B 12.5B 13.5B 16.5B 17B
Right-of-use assets (KRW) — — 0.00 888M 1.31B 1.1B 3.63B 3.1B 2.57B 2.09B
Net debt (borrowings + leases - cash) (KRW) -55.1B -72.2B -42.3B 3.17B 98.6B -23.1B 84.3B 142B 54.7B 48.2B
Cash flow detail
Operating cash flow (KRW) 50.8B 54.4B 10.8B -30.5B -20.9B 7.27B 7.03B 1.3B 109B 14B
Purchases of property, plant and equipment (KRW) -16B -27.7B -27.2B -6.22B -17B -51.8B -60.5B -43.2B -82.8B -47.1B
Purchases of intangible assets (KRW) -4.48M -40.3M -146M -92.8M -455M -126M -185M -199M -419M -214M
Dividends paid (cash effect) (KRW) -2.95B -9.24B -9.33B -9.33B — — -9.4B -9.4B -9.4B -10.1B
Interest paid (cash effect) (KRW) -1.57B -94.4M — -76.4M -435M -448M -930M -1.33B -817M -578M
Income taxes paid (cash effect) (KRW) -15.3B -21.9B -7.51B 297M -10.9M 827M -2.87B -2.12B -4.96B -8.74B
Free cash flow (OCF - PPE - intangibles) (KRW) 34.7B 26.7B -16.5B -36.8B -38.4B -44.6B -53.6B -42.1B 26.2B -33.3B
Income detail
Total comprehensive income (KRW) 58.2B 45.7B -10.2B -18.9B -12.7B — 19.5B 19.4B 32.3B 55.8B
Comprehensive income to owners (KRW) 58.2B 45.7B 0.00 -18.9B -11.7B 4.8B 19.8B 21.2B 34.5B 56.1B
Reported Mar 30, 2018 Aug 14, 2018 Mar 15, 2021 Mar 15, 2021 Mar 15, 2021 Mar 15, 2024 Aug 14, 2025 Aug 14, 2025 Aug 14, 2025 Jun 2, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

기업설명회(IR)개최 Bull 0 Bear 0 Routine

ST Pharm

ST Pharm

  • 01Who we are

  • 02Our record

  • 03Newsroom

  • 04Contact

  • Ko

ST Pharm

HOMEPublicPR (Public Relations)News roomAll

Public

All

All

Oct 28, 2026

[안내] 에스티팜, 미국 글로벌제약사와 261억원 규모 올리고핵산치료제 원료의약품 공급계약 체결

  • 에스티팜이 미국의 글로벌제약사와 신규 CDMO 프로젝트 2건 총 1,965만 달러 (약 261억원, 전일자 최종고시 매매기준율 1,327원/USD 적용) 규모 올리고핵산치료제 원료의약품 공급계약을 체결했습니다.

  • 해당 신규 프로젝트 2건은 각각 1,310만 달러 (납기 '27.12.31), 664만 달러 (납기 '27.10.30) 규모로 모두 글로벌 임상 2상이 진행 중입니다. 고객사와의 비밀유지 협약에 따라 적응증 등은 공개하지 않있습니다.

List

HOMEPublicPR (Public Relations)News roomAll

© 2026 ST Pharm. All rights reserved.

Prompts

ST PHARM (ticker 237690), listed in South Korea.

ETFs Holding ST PHARM

ETF Weight in ETF Shares Market value As of
AVEE 0.07% 1,759 $ 92.059K Nov 16, 2026
DFEM 0.01% 12,789 $ 700.754K Nov 12, 2026
DEXC 0.01% 336 $ 18.411K Nov 12, 2026
DFAE 0.00% 6,784 $ 371.719K Nov 12, 2026
DFSE 0.00% 281 $ 15.397K Nov 12, 2026
DFAX 0.00% 5,026 $ 275.392K Nov 12, 2026
AVEM 0.00% 4,811 $ 251.787K Nov 16, 2026
AVSE 0.00% 36 $ 1,884.09 Nov 16, 2026